Cargando…
Author Correction: Complement as a target in COVID-19?
Autores principales: | Risitano, Antonio M., Mastellos, Dimitrios C., Huber-Lang, Markus, Yancopoulou, Despina, Garlanda, Cecilia, Ciceri, Fabio, Lambris, John D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290154/ https://www.ncbi.nlm.nih.gov/pubmed/32533108 http://dx.doi.org/10.1038/s41577-020-0366-6 |
Ejemplares similares
-
Complement as a target in COVID-19?
por: Risitano, Antonio M., et al.
Publicado: (2020) -
The first case of COVID-19 treated with the complement C3 inhibitor AMY-101
por: Mastaglio, Sara, et al.
Publicado: (2020) -
Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy
por: Mastellos, Dimitrios C., et al.
Publicado: (2020) -
Complement-Dependent Mechanisms and Interventions in Periodontal Disease
por: Hajishengallis, George, et al.
Publicado: (2019) -
Efficacy matters: broadening complement inhibition in COVID-19
por: Mastellos, Dimitrios C, et al.
Publicado: (2021)